SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Savara Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.63+0.18 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 34.6% | -59.7% | -63.5% | |
| Return on assets | -26.3% | -42.4% | -51.0% | |
| Current ratio | 4.23 | 10.41 | 11.85 | |
| Debt to equity | – | 0.39 | 0.15 | |
| Net debt to EBITDA | – | -0.05× | 0.03× | |
| Interest coverage | -24.2× | – | – | |
| Capex to revenue | 2.0% | 18.3% | – | |
| Diluted shares | 2M | 59M | 222M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Savara generated $315.82M from operations and spent $409.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$315.82M
Used
$409.00K
Capital expenditure$409.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-19305.4%
×Asset turnover0.00×
×Equity multiplier1.41×
=Return on equity, FY2020-59.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2020 | -19305.4% | 0.00× | 1.41× | -59.7% |
| FY2016 | -2730.8% | 0.01× | -1.32× | 34.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$118.84M
- Cash generatingOperating cash flow above zero-$101.04M
- Return on assets improvedROA up on the prior year-54.0% → -55.8%
- Earnings backed by cashOperating cash flow above net income-$101.04M vs -$118.84M
- Less leverageLong-term debt to assets fell12.5% → 11.8%
- Better liquidityCurrent ratio rose13.73 → 11.85
- No dilutionShare count did not rise198M → 222M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –